Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03924505
Other study ID # INOD
Secondary ID 1R01DA046867-01
Status Recruiting
Phase N/A
First received
Last updated
Start date September 3, 2019
Est. completion date September 2021

Study information

Verified date September 2020
Source RTI International
Contact Barrot Lambdin, PhD, MPH
Phone 510-665-8254
Email blambdin@rti.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to generate knowledge regarding the process of implementing naloxone within syringe service programs (SSPs), and to test whether external facilitation can improve implementation of naloxone within SSPs throughout the country. Together, these efforts can improve access to naloxone for people at high risk of overdose, thereby improving our nation's response to the opioid overdose epidemic.


Description:

The purpose of this study is to understand and improve naloxone implementation within Syringe Service Programs (SSPs) to reduce opioid overdose mortality in the United States. To achieve this goal, we will implement an external facilitation intervention that has been shown to improve implementation in HIV service settings. The intervention will leverage a naloxone implementation expert who will work with SSP organizational directors to identify barriers to and facilitators of achieving naloxone implementation quality and maximizing reach. We propose to assess the effectiveness of external facilitation, compared to dissemination of an implementation manual, in a national sample of SSPs in a randomized controlled trial (RCT). Our proposed specific aims are as follows:

Aim 1: To characterize United States syringe service programs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering naloxone.

Aim 2: To test the effectiveness of external facilitation + dissemination of the naloxone implementation manual, compared with dissemination of the naloxone implementation manual alone, to improve the advancement of naloxone along the EPIS continuum among United States syringe service programs.

Hypothesis. The dissemination and external facilitation arm will be more effective in advancing naloxone implementation along the EPIS continuum between baseline and 12-month follow-up, than the dissemination-only arm.

To achieve these aims, 425 SSPs that are registered with the North American Syringe Exchange Network (NASEN) and /or receive information from harm reduction related web-based forums (e.g., online discussion groups, newsletters and listservs)will be asked to participate in an on-line cross-sectional survey and will be sent a hyperlink to the initial screening survey. We will use the on-line survey results to characterize the SSPs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering the naloxone intervention (AIM 1).

The on-line survey includes a set of questions designed to collect information to evaluate where the SSP falls along the EPIS continuum for naloxone delivery. SSPs in the Implementation (I) phase of the EPIS continuum (estimated n = 100) will be contacted by research staff and offered the opportunity to participate in the RCT. SSPs that are interested in participating in the RCT will be enrolled in the study. For those SSPs who agree to participate, study staff will confirm eligibility by reviewing and documenting responses to the screening survey.

Following informed consent procedures, the study staff will administer the baseline survey to the SSP representative. The baseline survey will include questions about programmatic capacity, organizational culture, potential for internal champion or leader, perceived need for naloxone distribution within their community, and community acceptance of peer naloxone distribution programming. The study staff will then randomize SSPs into one of the one of the two study arms: (1) dissemination of the implementation manual and external facilitation for 12 months (experimental arm; n=50) and (2) dissemination of the implementation manual only (control arm; n=50).

All SSPs enrolled in the RCT will be sent a copy of the naloxone implementation manual either via email, hyperlink or the U.S. postal service depending on the preference of the participant. Those SSPs in the experimental arm will be enrolled in the EF intervention during which they will work directly with an OC to advance naloxone delivery as far along the EPIS continuum as possible during a 12-month period. The intervention will be delivered via phone calls, web-enabled audio and screen-sharing technology, and site visits. The key activities of the EF intervention include, initial SSP engagement, knowledge enhancement, capacity assessment, information gathering, identification of barriers and facilitators, development of action plans and provision of feedback, identification of funding and linkage to resources, and training of SSP staff.

At the end of the 12-month intervention period, SSPs in both study arms will participate in a follow-up survey, conducted by study staff, to evaluate advancement of naloxone implementation along the EPIS continuum.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2021
Est. primary completion date September 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- SSPs that participate in the on-line screening survey and fall into the implementation phase of the EPIS continuum will be recruited into the study.

Exclusion Criteria:

-

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Implementation Manual with External Facilitation Intervention
Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation process-exploration, preparation, implementation and sustainment (EPIS).
Implementation Manual only
Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.

Locations

Country Name City State
United States RTI International Berkeley California

Sponsors (2)

Lead Sponsor Collaborator
RTI International National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adoption of Best Practices Number of Best Practices adopted by the SSP Baseline
Primary Adoption of Best Practices Number of Best Practices adopted by the SSP 12 months
Primary Naloxone Coverage Number of SSP participants receiving a dose of naloxone Baseline
Primary Naloxone Coverage Number of SSP participants receiving a dose of naloxone 12 months
Primary Number of Naloxone Doses Distributed to SSP participants Naloxone Dispensed Baseline
Primary Number of Naloxone Doses Distributed to SSP participants Naloxone Dispensed 12 months
See also
  Status Clinical Trial Phase
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Completed NCT05219669 - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Phase 1
Completed NCT04317053 - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program Phase 3
Not yet recruiting NCT06466005 - UnityPhilly Response App for Overdose Reversal
Recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Suspended NCT05114460 - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal Phase 2
Recruiting NCT06238128 - Opioid Rapid Response System: Naloxone Training in Communities N/A
Completed NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting NCT05944133 - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed NCT05377255 - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults Phase 1
Recruiting NCT05877118 - Improving Availability of Intranasal Naloxone N/A
Recruiting NCT05072249 - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn NCT05808881 - Clinical Outcomes From Nalmefene Phase 4
Not yet recruiting NCT01622504 - Naloxone Nasal Spray Pharmacokinetic Study Phase 1
Not yet recruiting NCT06429436 - Vending Machine Naloxone Distribution for Your Community (VENDY) Phase 4
Completed NCT05506267 - Development of a Tracheal Sound Sensor
Completed NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Not yet recruiting NCT06408714 - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Phase 3